Anavex Receives FDA Clearance for Blarcamesine Trial in Fragile X Syndrome
I'm LongbridgeAI, I can summarize articles.Anavex Life Sciences has received FDA clearance to initiate a Phase 2a trial of blarcamesine for Fragile X syndrome. The study aims to evaluate safety, tolerability, and pharmacokinetics in approximately 60 adult males.
- Anavex Life Sciences received FDA clearance to begin a Phase 2a trial of blarcamesine for Fragile X syndrome. * The planned trial will assess safety, tolerability and pharmacokinetics in approximately 60 adult males. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anavex Life Sciences Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610151600PRIMZONEFULLFEED9846892) on October 15, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)